home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
ARVINAS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
ARVINAS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
Post navigation
Previous Post
Previous
TRACON Pharmaceuticals Announces Publication Of Phase 1b Results For TRC105 In Combination With Inlyta® In Patients With Advanced Or Metastatic RCC
Next Post
Next
Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion